Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbbVie Inc (ABBV) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance

AbbVie IncTrade
iShares 0 3 Month Treasury Bond ETFTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs iShares 0 3 Month Treasury Bond ETF — how do they compare? AbbVie Inc trades at $249.5 (market cap $438.19B), while iShares 0 3 Month Treasury Bond ETF trades at $100.52. The key difference: AbbVie Inc pays a 2.79% dividend while iShares 0 3 Month Treasury Bond ETF pays none, and AbbVie Inc is trading nearer its 52-week high, iShares 0 3 Month Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.

ABBVSGOV
Market Cap
$438.19B
Sector
HealthFixed Income
52-Week High
$263.58$100.74
52-Week Low
$197.38$100.28
Enterprise Value
$502.45B
Dividend Yield
2.79%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.

Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.

iShares 0 3 Month Treasury Bond ETF

SGOV, the iShares 0-3 Month Treasury Bond ETF, trades at $100.48, showing minimal daily movement. The technical outlook is bearish based on moving averages, while oscillators are neutral. Recent news highlights institutional stake adjustments and investor interest in ultra-short Treasury ETFs as a defensive pivot amid market volatility, with articles noting its role as a conservative cash alternative offering a yield around 3.8% (Seeking Alpha, 2026-08-03).

The ETF provides exposure to short-term U.S. Treasury bills, benefiting from rising interest rates but facing risks from Federal Reserve policy uncertainty and inflation data. Its principal protection and monthly distributions appeal to risk-averse investors, though price appreciation is limited by its nature. Key risks include interest rate changes and macroeconomic shifts influencing Treasury yields.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Read more on ABBV

About iShares 0 3 Month Treasury Bond ETF

SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.

Read more on SGOV